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ment of her arteritis with antitumor necrosis factor-. Antitumor
necrosis factor- inhibits granuloma formation, and there are
many reports of tuberculosis after its use.5-6
As is the case with most vasculitides, the etiology of Takayasu
arteritis is not known. There is considerable overlap with other
syndromes of large-vessel arteritis. Not all evidence points toward
tuberculosis as a cause, and other pathophysiologic mechanisms
have been proposed. Nevertheless, the association between Taka-
yasu arteritis and Mycobacterium tuberculosis is an intriguing one
and awaits further study.
Ian R. McPhail, MD
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Reply
I thank Dr McPhail for his insightful and interesting com-
ments. I would certainly agree with him that we did not address the
etiology of Takayasu’s arteritis. The focus of the case report was to
describe a rare form of graft infection by Mycobacterium tubercu-
losis and its successful treatment as well as briefly summarize the
bacterial etiology and treatment of aortic graft infections in gen-
eral. It was not our intention to discuss the association of Takaya-
su’s arteritis with M. tuberculosis.
Dr McPhail has raised some very interesting issues about the
etiology of Takayasu’s arteritis and the possible connection with
tuberculosis. Of course there is a challenge in trying to attribute
causation (as with Crohn’s disease or sarcoidosis) as opposed to
association. The association between Takayasu’s arteritis and tu-
berculosis has been noted and is well referenced by Dr. McPhail.
But one third of the world’s population is infected with tubercu-
losis (World Health Organization), and that number is much
higher in India and similar places. Again, the association does not
ascribe causality: the same immune defect that causes the arteritis
may permit activation of latent tuberculosis infection.
To the best of our knowledge M. tuberculosis antigens have
not been found in the arterial wall of patients with Takayasu’s
arteritis or other vasculitides. We certainly agree with Dr McPhail
and the references provided that in the case we have described, the
patient’s quiescent tuberculosis was reactivated by infliximab
(Remicade, Centiocor, Inc, Malvern, Pa), an anti-tumor necrosis
factor- monoclonal antibody.
Joseph D. Raffetto, MD
VA Boston Healthcare System
West Roxbury, Mass
doi:10.1016/j.jvs.2005.02.016
Regarding “Ultrasound findings after radiofrequency
ablation of the great saphenous vein”
Wewould like to comment on the article by Salles-Cunha et al:
Ultrasound findings after radiofrequency ablation of the great
saphenous vein: Descriptive analysis (J Vasc Surg 2004;40:1166-
1173). The development of the radiofrequency (RF) closure tech-
nique for treating the incompetent great saphenous vein (GSV)
was completed by multiple specialties, with dermatology taking a
significant role.1,2 Dermatologic surgeons were the first to apply
tumescence to ambulatory phlebectomy and/or ligation of the
GSV and its tributaries.3,4 We therefore used tumescent anesthesia
with radiofrequency or other energies for endoluminal closure/
ablation of the GSV. Tumescent anesthesia or the placement of
large volumes of dilute anesthesia in a perivascular position serves
several purposes: first, to protect perivascular tissues from the
thermal effects of intravascular energy such as RF; second, to
decrease the diameter of the treated vein to allow for better contact
of the RF electrodes with the vein wall, and thus secondarily to
reduce intravascular blood for nonspecific coagulation; and third,
to provide better and safer anesthesia for patients. All of these
effects should serve to reduce perivascular inflammation.
Our initial results showed that tumescent anesthesia to treat
the GSV with endovenous techniques resulted in a painless proce-
dure with little down-time and immediate ambulation of the
patient.1,2,5,6 Regarding RF closure, we now have up to 5 years of
follow-up on 125 (M.P.G.) and 627 (R.A.W.) patients. We also
have treated patients with intravascular lasers, including the
810-nm diode laser, with up to 3 years of follow-up (75 patients,
M.P.G.; 36 patients, R.A.W.), and an additional 143 patients with
the 1,320-nm intravascular neodymium:yttrium-aluminum-garnet
laser with up to 2 years of follow-up (43 patients, M.P.G.; 121
patients, R.A.W.).7 Our combined clinical experience with en-
dovenous techniques spans 5.5 years, with well over 1,000 patient
treatments. Posttreatment duplex evaluation data at regular time
intervals exists on the vast majority of these patients.
Contrary to what is reported by Salles-Cunha et al, our expe-
rience with tumescent anesthesia used in every one of our patients
is a complete lack of small-vessel networks when patients are
evaluated postoperatively with duplex ultrasound. We believe that
the reason for our failure to find small-vessel networks is not a lack
of trying to see them but rather the minimization of inflammation
that occurs with tumescent anesthesia placed in the perivascular
space during either RF or laser endothelial ablation.
We have not performed ligation of the saphenofemoral junc-
tion (SFJ) on any of our over 1,000 patients and question the
accuracy of the findings of Salles-Cunha et al, who found a de-
creased incidence of small-vessel networks in patients whose SFJs
were ligated. We suspect that the small number of patients who
were treated without ligation of the SFJ (13) vs the 93 patients
who did have SFJ ligation produced the false statistical significance
of this finding. Alternatively, if inflammation is the most likely
cause for small vessel networks, why would ligation decrease the
extent or time of inflammation?
Finally, the investigators admit to performing ligation of all
tributary veins at the time of ligation at the SFJ. Could it be
possible that ligating and disrupting the normal vascular system at
the SFJ results in a decrease in the normal number of small-vessel
networks and that this accounts for the decrease seen in patients
operated on vs patients in whom only the RF is performed?
We are curious about why none of the five studies that we
published were not cited in the Salles-Cunha et al publica-
tion.1,2,5-7 We support efforts to share information across special-
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